Last reviewed · How we verify
A Multicenter Safety Clinical Trial of Ginkgolides Meglumine Injection in the Treatment of Ischemic Stroke With Syndrome of Intermingled Phlegm and Blood Stasis.
The aim of this study is to evaluate the safety of Ginkgolides Meglumine Injection in the treatment of ischemic stroke with Syndrome of Intermingled Phlegm and Blood Stasis.
Details
| Lead sponsor | Jiangsu Kanion Pharmaceutical Co., Ltd |
|---|---|
| Phase | Phase 4 |
| Status | COMPLETED |
| Enrolment | 6300 |
| Start date | 2013-06 |
| Completion | 2014-10 |
Conditions
- Ischemic Stroke
Interventions
- Ginkgolides Meglumine Injection
Primary outcomes
- Adverse Events — 14 days
Countries
China